APGE - Company ID 0001974640
The table below shows Apogee Therapeutics, Inc.'s income statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of revenue | - | - | - | - |
| Gross profit | - | - | - | - |
| R&D | $214.71M | $167.87M | $68.42M | $27.79M |
| SG&A | $70.88M | $49.01M | $24.58M | $2.94M |
| Operating income | -$285.60M | -$216.87M | -$93.00M | -$30.73M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Income tax | $278.00K | $18.00K | $0.00 | - |
| Net income | -$255.84M | -$182.15M | -$83.98M | -$39.78M |
| EPS (diluted) | -$4.22 | -$3.30 | -$3.36 | -$16.16 |